[CAS NO. 1357302-64-7] OG-L002

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1357302-64-7]

Catalog

SLK-S7237

Brand

Selleck

CAS

1357302-64-7

DESCRIPTION [1357302-64-7]

Overview

MDL	MFCD27997969
Molecular Weight	225.29
Molecular Formula	C15H15NO
SMILES	OC1=CC(C2=CC=C([C@@H]3[C@@H](N)C3)C=C2)=CC=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	4.4387 mL	22.1936 mL	44.3872 mL
5 mM	0.8877 mL	4.4387 mL	8.8774 mL
10 mM	0.4439 mL	2.2194 mL	4.4387 mL
50 mM	0.0888 mL	0.4439 mL	0.8877 mL

Description

OG-L002 is a potent and specific inhibitor with of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.

Features

This selective LSD1 inhibitor was discovered in 2013. Potential for use in viral diseases such as HSV and VZV.

Targets

LSD1 ^[1]
(Cell-free assay)

20 nM

In vitro

OG-L002 potently inhibits HSV IE gene expression in both HeLa and HFF cells with IC50 of ~10 μM and ~3 μM , respectively. OG-L002 treatment (50 μM ) results in the reduced production of progeny virus with no significant toxicity in HeLa or HFF cells. OG-L002 (50 μM ) increases the levels of repressive chromatin on viral IE gene promoters. In addition, OG-L002 also represses the expression of hCMV IE genes and adenovirus E1A gene.

In vivo

OG-L002 (6 to 40 mg/kg) represses HSV primary infection in a dose-dependent manner in a mouse model. Moreover, OG-L002 also represses HSV reactivation from latency in a mouse ganglion explant model.

References

[1] MBio. 2013, 4(1), e00558-12.